Company profile ZYME
After 39 days of this quarter the interest is at 175.0. Based on that we can calculate that during remaining 52 days it will total up to 408.0. Zanidatamab expected interest is significantly higher compared to previous quarter (+200.0%) and same quarter last year (+204.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 31 | 15 -51.6% QoQ | 67 346.7% QoQ | 73 9.0% QoQ |
| 2020 | 108 248.4% YoY 47.9% QoQ | 109 626.7% YoY 0.9% QoQ | 16 -76.1% YoY -85.3% QoQ | 69 -5.5% YoY 331.2% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 181 66.1% YoY inf% QoQ | 23 43.8% YoY -87.3% QoQ | 133 92.8% YoY 478.3% QoQ |
| 2022 | 82 inf% YoY -38.3% QoQ | 41 -77.3% YoY -50.0% QoQ | 162 604.3% YoY 295.1% QoQ | 146 9.8% YoY -9.9% QoQ |
| 2023 | 134 63.4% YoY -8.2% QoQ | 133 224.4% YoY -0.7% QoQ | 218 34.6% YoY 63.9% QoQ | 136 -6.8% YoY -37.6% QoQ |
| 2024 | 175 30.6% YoY 28.7% QoQ | - | - | - |
The average 5 years interest of Zanidatamab was 7.86 per week. The last year interest of Zanidatamab compared to the last 5 years has changed by 79.13%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 218.55%.
There is not enough data for Zanidatamab zovodotin to provide analysis
There is not enough data for Zanidatamab zovodotin to provide correlation calculation
There is not enough data for Zanidatamab zovodotin to provide analysis
There is not enough data for Zymeworks Zymeworks biotherapeutics to provide analysis
There is not enough data for Zymeworks Zymeworks biotherapeutics to provide correlation calculation
There is not enough data for Zymeworks Zymeworks biotherapeutics to provide analysis
There is not enough data for Zymeworks cancer treatment to provide analysis
There is not enough data for Zymeworks cancer treatment to provide correlation calculation
There is not enough data for Zymeworks cancer treatment to provide analysis
There is not enough data for HER2-targeted antibody-drug conjugate to provide analysis
There is not enough data for HER2-targeted antibody-drug conjugate to provide correlation calculation
There is not enough data for HER2-targeted antibody-drug conjugate to provide analysis
There is not enough data for biliary tract cancer treatment to provide analysis
There is not enough data for biliary tract cancer treatment to provide correlation calculation
There is not enough data for biliary tract cancer treatment to provide analysis
There is not enough data for gastroesophageal adenocarcinomas treatment to provide analysis
There is not enough data for gastroesophageal adenocarcinomas treatment to provide correlation calculation
There is not enough data for gastroesophageal adenocarcinomas treatment to provide analysis
After 39 days of this quarter the interest is at 292.0. Based on that we can calculate that during remaining 52 days it will total up to 681.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 500 | 769 53.8% QoQ | 728 -5.3% QoQ | 824 13.2% QoQ |
| 2020 | 833 66.6% YoY 1.1% QoQ | 668 -13.1% YoY -19.8% QoQ | 804 10.4% YoY 20.4% QoQ | 799 -3.0% YoY -0.6% QoQ |
| 2021 | 710 -14.8% YoY -11.1% QoQ | 728 9.0% YoY 2.5% QoQ | 726 -9.7% YoY -0.3% QoQ | 736 -7.9% YoY 1.4% QoQ |
| 2022 | 749 5.5% YoY 1.8% QoQ | 725 -0.4% YoY -3.2% QoQ | 732 0.8% YoY 1.0% QoQ | 747 1.5% YoY 2.0% QoQ |
| 2023 | 788 5.2% YoY 5.5% QoQ | 799 10.2% YoY 1.4% QoQ | 722 -1.4% YoY -9.6% QoQ | 814 9.0% YoY 12.7% QoQ |
| 2024 | 292 -62.9% YoY -64.1% QoQ | - | - | - |
The average 5 years interest of breast cancer treatment was 58.21 per week. The last year interest of breast cancer treatment compared to the last 5 years has changed by 0.86%. The interest for breast cancer treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -3.72%.
After 39 days of this quarter the interest is at 199.0. Based on that we can calculate that during remaining 52 days it will total up to 464.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 252 | 376 49.2% QoQ | 341 -9.3% QoQ | 415 21.7% QoQ |
| 2020 | 469 86.1% YoY 13.0% QoQ | 423 12.5% YoY -9.8% QoQ | 405 18.8% YoY -4.3% QoQ | 405 -2.4% YoY 0.0% QoQ |
| 2021 | 411 -12.4% YoY 1.5% QoQ | 549 29.8% YoY 33.6% QoQ | 406 0.2% YoY -26.0% QoQ | 338 -16.5% YoY -16.7% QoQ |
| 2022 | 499 21.4% YoY 47.6% QoQ | 524 -4.6% YoY 5.0% QoQ | 434 6.9% YoY -17.2% QoQ | 374 10.7% YoY -13.8% QoQ |
| 2023 | 491 -1.6% YoY 31.3% QoQ | 472 -9.9% YoY -3.9% QoQ | 368 -15.2% YoY -22.0% QoQ | 471 25.9% YoY 28.0% QoQ |
| 2024 | 199 -59.5% YoY -57.7% QoQ | - | - | - |
The average 5 years interest of colorectal cancer treatment was 33.03 per week. The last year interest of colorectal cancer treatment compared to the last 5 years has changed by 4.75%. The interest for colorectal cancer treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 13.37%.
After 39 days of this quarter the interest is at 135.0. Based on that we can calculate that during remaining 52 days it will total up to 315.0. endometrial cancer treatment expected interest is significantly lower compared to same quarter last year (-56.3%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 305 | 528 73.1% QoQ | 441 -16.5% QoQ | 369 -16.3% QoQ |
| 2020 | 360 18.0% YoY -2.4% QoQ | 416 -21.2% YoY 15.6% QoQ | 472 7.0% YoY 13.5% QoQ | 340 -7.9% YoY -28.0% QoQ |
| 2021 | 284 -21.1% YoY -16.5% QoQ | 537 29.1% YoY 89.1% QoQ | 424 -10.2% YoY -21.0% QoQ | 396 16.5% YoY -6.6% QoQ |
| 2022 | 589 107.4% YoY 48.7% QoQ | 547 1.9% YoY -7.1% QoQ | 466 9.9% YoY -14.8% QoQ | 465 17.4% YoY -0.2% QoQ |
| 2023 | 721 22.4% YoY 55.1% QoQ | 595 8.8% YoY -17.5% QoQ | 671 44.0% YoY 12.8% QoQ | 493 6.0% YoY -26.5% QoQ |
| 2024 | 135 -81.3% YoY -72.6% QoQ | - | - | - |
The average 5 years interest of endometrial cancer treatment was 36.61 per week. The last year interest of endometrial cancer treatment compared to the last 5 years has changed by 21.33%. The interest for endometrial cancer treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 29.54%.